229 related articles for article (PubMed ID: 15948100)
1. Improvement of serum NT-ProBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure.
Yu CM; Fung JW; Zhang Q; Chan CK; Chan I; Chan YS; Kong SL; Sanderson JE; Lam CW
J Card Fail; 2005 Jun; 11(5 Suppl):S42-6. PubMed ID: 15948100
[TBL] [Abstract][Full Text] [Related]
2. Combination of left ventricular reverse remodeling and brain natriuretic peptide level at one year after cardiac resynchronization therapy predicts long-term clinical outcome.
Roubicek T; Stros J; Kucera P; Nedbal P; Cerny J; Polasek R; Wichterle D
PLoS One; 2019; 14(7):e0219966. PubMed ID: 31314790
[TBL] [Abstract][Full Text] [Related]
3. Longer right to left ventricular activation delay at cardiac resynchronization therapy implantation is associated with improved clinical outcome in left bundle branch block patients.
Kosztin A; Kutyifa V; Nagy VK; Geller L; Zima E; Molnar L; Szilagyi S; Ozcan EE; Szeplaki G; Merkely B
Europace; 2016 Apr; 18(4):550-9. PubMed ID: 26116830
[TBL] [Abstract][Full Text] [Related]
4. Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study.
Berger R; Shankar A; Fruhwald F; Fahrleitner-Pammer A; Freemantle N; Tavazzi L; Cleland JG; Pacher R
Eur Heart J; 2009 Sep; 30(17):2109-16. PubMed ID: 19493864
[TBL] [Abstract][Full Text] [Related]
5. Clinical, echocardiographic, and neurohormonal response to cardiac resynchronization therapy: are they interchangeable?
Hoogslag GE; Höke U; Thijssen J; Auger D; Marsan NA; Wolterbeek R; Holman ER; Schalij MJ; Bax JJ; Verwey HF; Delgado V
Pacing Clin Electrophysiol; 2013 Nov; 36(11):1391-401. PubMed ID: 23826659
[TBL] [Abstract][Full Text] [Related]
6. Cardiorenal status using amino-terminal pro-brain natriuretic peptide and cystatin C on cardiac resynchronization therapy outcomes: From the BIOCRT Study.
Truong QA; Szymonifka J; Januzzi JL; Contractor JH; Deaño RC; Chatterjee NA; Singh JP
Heart Rhythm; 2019 Jun; 16(6):928-935. PubMed ID: 30590191
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population.
Sokal A; Lenarczyk R; Kowalski O; Mitrega K; Pluta S; Stabryla-Deska J; Streb W; Urbanik Z; Krzeminski TF; Kalarus Z
Heart Rhythm; 2016 May; 13(5):1088-1095. PubMed ID: 26776557
[TBL] [Abstract][Full Text] [Related]
8. NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF.
Daubert MA; Adams K; Yow E; Barnhart HX; Douglas PS; Rimmer S; Norris C; Cooper L; Leifer E; Desvigne-Nickens P; Anstrom K; Fiuzat M; Ezekowitz J; Mark DB; O'Connor CM; Januzzi J; Felker GM
JACC Heart Fail; 2019 Feb; 7(2):158-168. PubMed ID: 30611722
[TBL] [Abstract][Full Text] [Related]
9. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
[TBL] [Abstract][Full Text] [Related]
10. Cardiac resynchronization therapy in patients with heart failure and moderately reduced ejection fraction: Could it trigger a super-response?
Tawfik Ghanem M; Allam LE; Samir Ahmed R
Indian Heart J; 2019; 71(3):229-234. PubMed ID: 31543195
[TBL] [Abstract][Full Text] [Related]
11. Cardiac resynchronization therapy in pacemaker-dependent patients with left ventricular dysfunction.
Gierula J; Cubbon RM; Jamil HA; Byrom R; Baxter PD; Pavitt S; Gilthorpe MS; Hewison J; Kearney MT; Witte KK
Europace; 2013 Nov; 15(11):1609-14. PubMed ID: 23736807
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
[TBL] [Abstract][Full Text] [Related]
13. Pro-brain natriuretic peptide plasma levels, left ventricular dimensions and ejection fraction in acute dyspnoea.
Shaikh K; Hanif B; Siddique AA; Shaikh MY; Khan MN
J Coll Physicians Surg Pak; 2012 Dec; 22(12):751-5. PubMed ID: 23217478
[TBL] [Abstract][Full Text] [Related]
14. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study.
Truong QA; Januzzi JL; Szymonifka J; Thai WE; Wai B; Lavender Z; Sharma U; Sandoval RM; Grunau ZS; Basnet S; Babatunde A; Ajijola OA; Min JK; Singh JP
Heart Rhythm; 2014 Dec; 11(12):2167-75. PubMed ID: 25014756
[TBL] [Abstract][Full Text] [Related]
15. Decrease of plasma N-terminal pro beta-type natriuretic peptide as a predictor of clinical improvement after cardiac resynchronization therapy for heart failure.
Ding LG; Hua W; Zhang S; Chu JM; Chen KP; Wang Y; Wang FZ; Chen X
Chin Med J (Engl); 2009 Mar; 122(6):617-21. PubMed ID: 19323922
[TBL] [Abstract][Full Text] [Related]
16. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.
Cleland J; Freemantle N; Ghio S; Fruhwald F; Shankar A; Marijanowski M; Verboven Y; Tavazzi L
J Am Coll Cardiol; 2008 Aug; 52(6):438-45. PubMed ID: 18672164
[TBL] [Abstract][Full Text] [Related]
17. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
[TBL] [Abstract][Full Text] [Related]
18. Immediate and chronic effects of AV-delay optimization in patients with cardiac resynchronization therapy.
Hardt SE; Yazdi SH; Bauer A; Filusch A; Korosoglou G; Hansen A; Bekeredjian R; Ehlermann P; Remppis A; Katus HA; Kuecherer HF
Int J Cardiol; 2007 Feb; 115(3):318-25. PubMed ID: 16891011
[TBL] [Abstract][Full Text] [Related]
19. Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study.
Gaggin HK; Truong QA; Rehman SU; Mohammed AA; Bhardwaj A; Parks KA; Sullivan DA; Chen-Tournoux A; Moore SA; Richards AM; Troughton RW; Lainchbury JG; Weiner RB; Baggish AL; Semigran MJ; Januzzi JL
Congest Heart Fail; 2013; 19(3):135-42. PubMed ID: 23279139
[TBL] [Abstract][Full Text] [Related]
20. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).
Stienen S; Salah K; Moons AH; Bakx AL; van Pol P; Kortz RAM; Ferreira JP; Marques I; Schroeder-Tanka JM; Keijer JT; Bayés-Genis A; Tijssen JGP; Pinto YM; Kok WE
Circulation; 2018 Apr; 137(16):1671-1683. PubMed ID: 29242350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
